The safety and efficacy of fosphenytoin for the treatment of status epilepticus

References

• Moshé SL, Perucca E, Ryvlin P, Tomson T. Epilepsy: new advances. Lancet 2015;385(9971):884-98
   PubMed Web of Science ®Google Scholar
• Eriksson K, Keränen T, Kälviäinen R. Fosphenytoin. Expert Opin Metab. Toxicol 2009;5(6):695-701
   PubMed Web of Science ®Google Scholar
• Dham BS, Hunter K, Rincon F. The epidemiology of status epilepticus in the United States. Neurocrit Care 2014;20(3):476-83
   PubMed Web of Science ®Google Scholar
• Fischer JH, Patel TV, Fischer PA. Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures. Clin Pharmacokinet 2003;42(1):33-58
   PubMed Web of Science ®Google Scholar
• Bleck T, Cock H, Chamberlain J, et al. The established status epilepticus trial. Epilepsia 2013;54(Suppl 6):89-92
   Google Scholar
• Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the Eight Eilat Conference (EILAT VIII). Epilepsy Res 2007;73(1):1-52
   PubMed Web of Science ®Google Scholar
• Tanaka J, Kasai H, Shimizu K, et al. Population pharmacokinetics of phenytoin after intravenous administration of fosphenytoin sodium in pediatric patients, adult patients, and healthy volunteers. Eur J Clin Pharmacol 2013;69(3):489-97
   PubMed Web of Science ®Google Scholar
• Hussey EK, Dukes GE, Messenheimer JA, et al. Evaluation of the pharmacokinetic interaction between diazepam and ACC-9653 (a phenytoin prodrug) in healthy male volunteers. Pharm Res 1990;7(11):1172-6
   PubMed Web of Science ®Google Scholar
• Nakazawa M, Akasaka M, Hasegawa T, et al. Efficacy and safety of fosphenytoin for acute encephalopathy in children. Brain Dev 2015;37(4):418-22
   PubMed Web of Science ®Google Scholar
• Abend NS, Loddenkemper T. Management of pediatric status epilepticus. Curr Treat Options Neurol 2014;16(7):301
   PubMed Web of Science ®Google Scholar
• Łuszczki JJ. Third-generation antiepileptic drugs: mechanism of action, pharmacokinetics and interactions. Pharmacol Rep 2009;61(2):197-216
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. NDA 020450 Cerebyx (fosphenytoin sodium) Injection. 2013. Available from: www.accessdata.fda.gov/drugsatfdadocs/label/2013/020450s020lbl.pdf
   Google Scholar
• Sánchez Fernández I, Loddenkemper T. Therapeutic choices in convulsive status epilepticus. Expert Opin Pharmacother 2015;16(4):487-500
   PubMed Web of Science ®Google Scholar
• Browne TR, Kugler AR, Eldon MA. Pharmacology and pharmacokinetics of fosphenytoin. Neurology 1996;46(6 Suppl 1):3-7
   PubMed Web of Science ®Google Scholar
• Inoue Y, Usui N, Hiroki T, et al. Bioavailability of intravenous fosphenytoin sodium in healthy Japanese volunteers. Eur J Drug Metab Pharmacokinet 2013;38(2):139-48
   PubMed Web of Science ®Google Scholar
• Horowitz BZ. Fosphenytoin farewell? Ann Emerg Med 2004;43(3):398-400
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V). Epilepsy Res 2001;43(1):11-58
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the sixth eilat conference (EILAT VI). Epilepsy Res 2002;51(1):31-71
   PubMed Web of Science ®Google Scholar
• Tunnicliff G. Basis of the antiseizure action of phenytoin. Gen Pharmacol 1996;27(7):1091-7
   PubMedGoogle Scholar
• Gerber N, Mays DC, Donn KH, et al. Safety, tolerance and pharmacokinetics of intravenous doses of the phosphate ester of 3-hydroxymethyl-5,5-diphenylhydantoin: a new prodrug of phenytoin. J Clin Pharmacol 1998;28(11):1023-32
   Google Scholar
• Leppik IE, Boucher BA, Wilder BJ, et al. Pharmacokinetics and safety of a phenytoin prodrug given i.v. or i.m. in patients. Neurology 1998;28(11):1023-32
   Google Scholar
• Lai CM, Moore P, Quon CY. Binding of fosphenytoin, phosphate ester pro drug of phenytoin, to human serum proteins and competitive binding with carbamazepine, diazepam, phenobarbital, phenylbutazone, phenytoin, valproic acid and warfarin. Res Commun Mol Pathol Pharmacol 1995;88(1):51-62
   PubMed Web of Science ®Google Scholar
• Jamerson BD, Donn KH, Dukes GE, et al. Absolute bioavailability of phenytoin after 3-phosphoryloxymethyl phenytoin disodium (ACC-9653) administration to humans. Epilepsia 1990;31(5):592-7
   PubMed Web of Science ®Google Scholar
• Empey PE, de Mendizabal NV, Bell MJ, et al. Therapeutic hypothermia decreases phenytoin elimination in children with traumatic brain injury. Crit Care Med 2013;41(10):2379-87
   PubMed Web of Science ®Google Scholar
• Ahn JE, Cloyd JC, Brundage RC, et al. Phenytoin half-life and clearance during maintenance therapy in adults and elderly patients with epilepsy. Neurology 2008;71(1):38-43
   PubMed Web of Science ®Google Scholar
• Aweeka FT, Gottwald MD, Gombertoglio JG, et al. Pharmacokinetics of fosphenytoin in patients with hepatic of renal disease. Epilepsia 1999;40(6):777-82
   PubMed Web of Science ®Google Scholar
• McBryde KD, Wilcox J, Kher KK. Hyperphosphatemia due to fosphenytoin in a pediatric ESRD patient. Pediatr Nephrol 2005;20(8):1182-5
   PubMed Web of Science ®Google Scholar
• Ogutu BR, Newton CRJC, Muchohi SN, et al. Pharmacokinetics and clinical effects of phenytoin and fosphenytoin in children with severe malaria and status epilepticus. Br J Clin Pharmacol 2003;56(1):112-19
   PubMed Web of Science ®Google Scholar
• Takeoka M, Krishnamoorthy KS, Soban TB, Caviness VSJr. Fosphenytoin in infants. J Child Neurol 1998;13(11):537-40
   PubMed Web of Science ®Google Scholar
• Kriel RL, Cifuentes RF. Fosphenytoin in infants of extremely low birth weight. Pediatr Neurol 2001;24(3):2019-21
   Web of Science ®Google Scholar
• Bansal S, Blalock D, Kebede T, et al. Levetiracetam versus (fos)phenytoin for seizures prophylaxis in pediatric patients with intracranial haemorrhage. J Neurosurg Pediatr 2014;13(2):209-15
   PubMed Web of Science ®Google Scholar
• Nakazawa M, Toda S, Abe S, et al. Efficacy and safety of fosphenytoin for benign convulsions with mild gastroenteritis. Brain Dev 2015. [Epub ahead of print]
   Google Scholar
• Okumura A, Uemura N, Negoro T, Watanabe K. Efficacy of antiepileptic drugs in patients with benign convulsions with mild gastroenteritis. Brain Dev 2004;26(3):164-7
   PubMed Web of Science ®Google Scholar
• Uemura N, Okumura A, Negoro T, Watanabe K. Clinical features of benign convulsions with mild gastroenteritis. Brain Dev 2002;24(8):745-9
   PubMed Web of Science ®Google Scholar
• Szaflarski JP, Sangha KS, Lindsell CJ, Shutter LA. Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis. Neurocrit Care 2010;12(2):165-72
   PubMed Web of Science ®Google Scholar
• Clinical trials on fosphenytoin. Available from: https://clinicaltrials.gov/ct2/results?term=fosphenytoin&Search=Search
   Google Scholar
• Connor JT, Elm JJ, Broglio KR; ESETT, ADAPT-IT Investigators. Bayesian adaptive trials offer advantages in comparative effectiveness trials: an example in status epilepticus. J Clin Epidemiol 2013;66(8 Suppl):130-7
   Web of Science ®Google Scholar
• Husain AM. Treatment of recurrent electrographic nonconvulsive seizures (TRENdS) study. Epilepsia 2013;66(8 Suppl):130-7
   Google Scholar
• Ramsay RE, Wilder BJ, Uthman BM, et al. Intramuscular fosphenytoin (Cerebyx) in patients requiring a loading dose of phenytoin. Epilepsy Res 1997;28(3):181-7
   PubMed Web of Science ®Google Scholar
• Adams BD, Buckley NH, Kim JY, Tipps LB. Fosphenytoin may cause hemodynamically unstable bradyarrhythmias. J Emerg Med 2006;30(1):75-9
   PubMed Web of Science ®Google Scholar
• Keegan MT, Bondy LR, Blackshear JL, Lanier WL. Hypocalcemia-like electrocardiographic changes after administration of intravenous fosphenytoin. Mayo Clin Proc 2002;77(6):584-6
   PubMed Web of Science ®Google Scholar
• Pellock JM. Fosphenytoin use in children. Neurology 1996;46(6 Suppl 1):14-16
   PubMed Web of Science ®Google Scholar
• Wasim M, Husain AM. Nonconvulsive seizure control in the intensive care unit. Curr Treat Options Neurol 2015;17(3):340
   PubMed Web of Science ®Google Scholar
• Jankovic SM, Dostic M. Choice of antiepileptic drugs for the elderly: possible drug interactions and adverse effects. Expert Opin Metab Toxicol 2012;8(1):81-91
   PubMed Web of Science ®Google Scholar
• Shaikh AG, Ghasia FF. Physiology and pathology of saccades and gaze holding. NeuroRehabilitation 2013;32(3):493-505
   PubMed Web of Science ®Google Scholar
• Rudis MI, Touchette DR, Swadron SP, et al. Cost-effectiveness of oral phenytoin, intravenous phenytoin, and intravenous fosphenytoin in the emergency department. Ann Emerg Med 2004;43(3):386-97
   PubMed Web of Science ®Google Scholar
• Thomson A. Fosphenytoin for the treatment of status epilepticus: an evidence-based assessment of its clinical and economic outcomes. Core Evid 2005;1(1):65-75
   PubMedGoogle Scholar
• Florek-Luszczki M, Wlaz A, Luszczki JJ. Interactions of levetiracetam with carbamazepine, phenytoin, topiramate and vigabatrin in the mouse 6Hz psychomotor seizure model – a type II isobolographic analysis. Eur J Pharmacol 2014;723:410-18
   PubMed Web of Science ®Google Scholar
• Luszczki JJ, Andres MM, Czuczwar P, et al. Pharmacodynamic and pharmacokinetic characterization of interactions between levetiracetam and numerous antiepileptic drugs in the mouse maximal electroshock seizure model: an isobolographic analysis. Epilepsia 2006;47(1):10-20
   PubMed Web of Science ®Google Scholar
• Borowicz KK, Swiader M, Luszczki J, Czuczwar SJ. Effect of gabapentin on the anticonvulsant activity of antiepileptic drugs against electroconvulsions in mice: an isobolographic analysis. Epilepsia 2002;43(9):956-63
   PubMed Web of Science ®Google Scholar
• Dela Cruz FG, Kanter MZ, Fischer JH, Leikin JB. Efficacy of individualized phenytoin sodium loading doses administered by intravenous infusion. Clin Pharm 1988;7(3):219-24
   PubMedGoogle Scholar
• Patterson EE, Leppik IE, Coles LD, et al. Canine status epilepticus treated with fosphenytoin: A proof of principle study. Epilepsia 2015;56(6):882-7
   PubMed Web of Science ®Google Scholar
• Coles LD, Leppik IE, Patterson EE, et al. Use of IV fosphenytoin pharmacokinetics to determine the loading dose for a clinical trial of canine status epilepticus. Epilepsia 2015;56(6):888-94
   PubMed Web of Science ®Google Scholar